Combination therapy for advanced HER2 breast cancer after T-DXd
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs for people whose breast cancer has stopped responding to a targeted therapy called T-DXd (Enhertu). The goal is to find out if adding a second drug can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your breast cancer must have spread to other parts of the body (metastatic) and be HER2-positive, HER2-low, or HER2-ultralow.
- You must have already been treated with the drug T-DXd (Enhertu) and your cancer continued to grow.
- You should be able to do light activities and take care of yourself (ECOG 0-2).
- Your blood counts, liver, and kidney function must be within certain limits.
- If you have brain tumors, they must be stable or already treated.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.
This trial compares two treatments for advanced breast cancer that is HR-positive, HER2-low or ultralow, and a non-luminal subtype. It tests if a targeted antibody-drug conjugate (T-DXd) works better than the usual first-line therapy combining a CDK4/6 inhibitor with hormone therapy. This study is for people who have not had any treatment for advanced disease.
This study is testing a drug called T-DXd (a targeted therapy) in people with advanced breast cancer that has HER2 overexpression or underexpression. It looks at how well the drug works in real-world settings, which may provide a new treatment option if your cancer has progressed.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This trial tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Hear when a new T-dxd Resistant HER2-Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.